C-1YVUpartial epigenetic reprogramming, cellular rejuvenation, OSK gene therapy
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Life Biosciences partial epigenetic reprogramming, cellular rejuvenation, OSK gene therapy
Life Biosciences is a clinical-stage biotechnology company developing cellular rejuvenation therapies to reverse and prevent multiple diseases of aging. Its proprietary Partial Epigenetic Reprogramming platform uses OCT4, SOX2, and KLF4 to restore older and damaged cells to a younger and healthier state. The lead program, ER-100, is in development for optic neuropathies including open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy, with a Phase 1 clinical trial initiated in the first quarter of 2026.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Life Biosciences — Translational · Bottom quartile. Derived deterministically from 5 extracted project(s). Most-advanced status: phase 1. Band: translational. Modifiers: +5 depth (3 programs at…
Source: Deterministic